
#Radonc, brain tumor & lung cancer specialist @TurvilleBay Outspoken advocate for my patients & field. Dad. #btsm #lcsm
Madison, WI
Joined October 2017
- Tweets1.5K
- Following722
- Followers2.3K
- Likes7.7K
Pinned Tweet
I think we need to all just need pause & reflect.
A football field worth of oncologists are here to hear a REAL DEBATE on a question we wouldn’t have asked 10 years ago.
CURING metastatic disease with RT + IO??
What an exciting time to be an oncologist! #astro19
Tim Kruser retweeted
Lastly, we were also able to utilize the RTOG-0539 clinical trial cases for biomarker discovery and build multiple molecular predictive models of response to RT that were able to predict PFS following RT in meningiomas better than WHO grade alone including being able to identify RT-resistant meningiomas in each WHO grade
Tim Kruser retweeted
Glad to share some of my PhD work on using molecular classification to predict outcomes following surgery and radiotherapy in meningiomas published in @NatureMedicine.
Grateful to @gelarehzadeh and @FarshadNassiri for helping guide this work and to our collaborators, reviewers, and funding agencies.
nature.com/articles/s41591-0…
Tim Kruser retweeted
The Lahey Lung Cancer Screening program has surpassed 30,000 scans
10,500 patients scanned
382 lung cancers detected
Cancer detection rate of 3.65%
0.0095 rate of any invasive procedure in patients without cancer
Lung Cancer Screening is SAFE and EFFECTIVE
Tim Kruser retweeted
What I learned in 🇨🇱 today … $5mill = one #radiotherapy machine☢️, can treat 10k patients. $5mill = 135 patients worth of trastuzumab. 🧐
@TheLancetOncol - tinyurl.com/6bry9a2a “an essential pillar in multi-D oncology…an inexpensive modality” - 👏🏽 well said @TargetingCancer
Tim Kruser retweeted
3/ There are >dozen clinical trials of SABR for primary RCC – outlined in @ISRSy practice guideline - shorturl.at/suPTW – compared to zero for thermal ablation. The weight of evidence is with SABR, not TA, and is arguably the preferred modality for non-surgical therapy
Tim Kruser retweeted
Some like it hot! See oncoscan commentary on the subject ➡️ redjournal.org/article/S0360…
@DrewMoghanaki @UCD_radonc @TimothyKruserMD @MeredithGiulia1 @IJROBP 🐺#radonc
10 years of experience at the University Hospital of Liège in Belgium (2010-2020) demonstrates the importance of >110% hotspots in lung SBRT plans. #radonc ncbi.nlm.nih.gov/pmc/article…
Tim Kruser retweeted
So let me get this straight. More people in the U.S. die of lung cancer than die of breast, colorectal, and prostate cancer combined, and lung cancer screening rates are lower, yet @TODAYshow fails to mention it in their cancer screening segment? Who is their medical consultant?
We appreciate @TODAYshow for raising awareness of cancer screenings. However, we would have loved to have seen #lungcancer included. Lung cancer is the deadliest cancer. But only 4.5% of high risk Americans are getting screened. We need a segment on lung cancer screening! #LCAM🤍
Tim Kruser retweeted
I'm increasingly escalating RT dose for high-risk #meningioma in my practice @UCSF @UCSFCancer @NeurosurgUCSF. There is retrospective data in support of this approach, and now we have prospective data from @maxiydeng1994 in @NeuroOnc! Summary here: academic.oup.com/neuro-oncol…
Tim Kruser retweeted
Randomised CURB trial published in The Lancet:
👉 PFS increase by factor of FOUR (!) in oligoprogressive metastatic NSCLC pts by SBRT plus SoC vs SoC systemic Tx only
👉 SBRT with minimal added toxicity 16% G2+
Precision local SBRT🤝precision systemic TX
thelancet.com/journals/lance…
Tim Kruser retweeted
📢Do you remember this excellent letter? it seems like so little time has passed..similar trial omitting RT in BM 🟰same answer!!
"caution against overinterpretation of Atezo-Brain study and its impact on the management of intracranial disease in NSCLC patients"
Tim Kruser retweeted
ascopubs.org/doi/10.1200/JCO…
Thank you @JCO_ASCO for publishing our letter regarding the recent Atezo-Brain trial. @ASTRO_org #btsm #radonc
Tim Kruser retweeted
7) For those without subscription to @TheLancet, here’s the link to download the article:
urldefense.com/v3/__https://…
@simonpowell213 @JYangMDPhD @MSK_RadOnc @MSKCancerCenter @xrtGenomics @RadMedPM @RadOncMTD @pmcancercentre @imrtlee @charlesrudin @AmyXuMDPhD @drdavidpalma @ASTRO_org
Tim Kruser retweeted
Even in the ePET neg group with Hodgkin's Lymphoma, we cannot omit RT. H10 long-term FU showed. ePET + No difference between standard ABVD & exp intensified BEACOPPesc. Also icing on the cake no increase in second malignancies.
Tim Kruser retweeted
In three recent publications @jackykruser (@uw_APCC)—who just won the department's 2023 Junior Faculty Outstanding Research Award—shows how closer attention to communication can lead to meaningful changes in critical care practice: medicine.wisc.edu/news/jacqu…
Tim Kruser retweeted
What are the cognitive outcomes for glioma w/ modern focal RT?
· Prospective Study F/U up to 11 years!
· Stable w/some improvement
· Despite more aggressive tumors outcomes comparable to Watchful-Waiting cohort
rdcu.be/dmmHV
Tim Kruser retweeted
Dr Denise Bernhardt shows RCT of #radiosurgery versus whole brain #radiotherapy for small cell #lungcancer.
➡️Primary endpoint cognitive decline. #lcsm
➡️ 24% decline in WBRT versus 7% in SRS alone
OS data to mature!👏🏽👏🏽👏🏽
#ASTRO23
Tim Kruser retweeted
The Italian trial was fantastic. Really demonstrated what many radiation oncologists that specialize in mesothelioma had been seeing in their clinic. Hemithoracic radiation is much less morbid than surgery which likely explains the different outcome in the two trials.
Will def be an uphill battle for local tx after MARS2. I keep coming back to the trial by Trovo et al. (redjournal.org/article/S0360…), which has not received the attention it deserves IMO. Perhaps chemo/IO + RT (IMRT; moderate dose) could find balance between local control & tox?
Tim Kruser retweeted
Will def be an uphill battle for local tx after MARS2. I keep coming back to the trial by Trovo et al. (redjournal.org/article/S0360…), which has not received the attention it deserves IMO. Perhaps chemo/IO + RT (IMRT; moderate dose) could find balance between local control & tox?
Tim Kruser retweeted
The EORTC is conducting a consensus project to establish a consensual definition of resectability in stage III NSCLC. Bulky N2, invasive N2, N3-combinations were considered unresectable and should NOT be operated even after neoadjuvant chemo/RT outside clinical studies.#WCLC





































